Clinical Lab Industry News

A third of Phase 2 clinical trials were terminated in 2024, a 50 percent increase from before the pandemic

First and only molecular blood test that can both identify bacterial and viral infections and assess need for critical care

Acquisition will focus on expertise and innovation for diagnostics and healthcare customers

This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testosterone levels

To prepare for if the current H5N1 outbreak worsens, Hologic will work with the CDC to develop reagents that may be used for H5N1 testing

Sabrina Reilly has been named chief membership and market development officer for ADLM, effective December 10

With syphilis cases on the rise, NOWDx’s over-the-counter test offers rapid, in-home results in minutes and is now available nationwide in thousands of pharmacies and drugstore locations

The test enables precise detection of a range of complex genomic alterations that are features of many rare diseases and undetectable by traditional approaches

World’s first enhanced small particle (ESP™) detection sorter enables effective content isolation; opens door to scientific discoveries

Recent new and emerging technologies in the field of laboratory medicine from the 2024 November Genetics & Genomics issue of Today's Clinical Lab

New integrated automation system consolidates 25 tasks typically handled manually by lab staff

IntelliSep is the first and only FDA-cleared cellular host diagnostic indicated for use in the ED

Labcorp to serve as the exclusive NOWDiagnostics (NOWDx) distributor for clinical testing in the US, offering First to Know® Syphilis Test nationwide

Life sciences organizations can rapidly build AI algorithms to discover biomarkers, optimize clinical trials, and advance companion diagnostics

Enhances efficiency and reduces costs with all-in-one instrument for either IVD assays or tests designed and used by laboratories, user-friendly software and flexible scheduling features

ETD001 commenced Phase 2 clinical trials in July 2024, expected to complete in 2025

The new CPT code establishes a reimbursement pathway for increased access and broader test adoption for patients at high risk for ovarian cancer

Product line earns CE-marking under new EU IVDR framework—including QIAstat-Dx Analyzer, QIAstat-Dx Rise and panels for detection of gastrointestinal and respiratory infections

New CLIA-certified lab ensures seamless transition from early assay development and testing to full companion diagnostics commercialization

There’s been a 36 percent increase in cases of primary and secondary syphilis since 2021